Gyre Therapeutics, Inc.
NASDAQ:GYREBiotechnology
+$0.00 today
- Market cap
- $475.02M
- Beta
- 4.92
- P/E (TTM)
- -88.3
- EPS (TTM)
- -$0.07
Volume 0.47M
Average 0.09M
GYRE Net Change in Cash
Combined operating, investing, financing, and currency effects on the cash balance during the period.
Gyre Therapeutics, Inc.NASDAQ: GYRE
Net Change in Cash · Q1 FY2026 · quarter ended Mar 2026
Net change in cash dips below year-ago levels
Q1 FY2026 net change in cash of $431K fell 86.7% year over year, behind the +252.3% change in trailing-twelve-month net change in cash.
Context
- Net change in cash amounted to 21.7% of revenue in FY2025, up 1.1 pp from a year earlier.
- Net change in cash increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -86.7% toward the trailing-twelve-month pace of +252.3%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Net Change in Cash history
USD · from the cash flow
- Latest · FY2025
- 25.26M USD
- Year-over-year change
- +216.4%
- 4-year CAGR
- +15.9%
| Period | Period end | Net Change in Cash | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 25.26M | +216.4% |
| FY2024 | 2024-12-31 | (21.7M) | -360.3% |
| FY2023 | 2023-12-31 | 8.33M | +265.8% |
| FY2022 | 2022-12-31 | (5.03M) | -135.9% |
| FY2021 | 2021-12-31 | 13.99M | — |
Net Change in Cash vs competitors
How GYRE compares with its peers on the latest reported figures
- GYRE's LTM Mar 2026 net change in cash of $22.46M is the 2nd largest of the 4 companies compared; the peer median is $5.27M.
- Its year-over-year change of +252.3% is the highest of 4, against a peer median of +141.4%.
- Net change in cash amounts to 19.2% of revenue for GYRE, versus a peer median of 70.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $69.75M | +211.9% | +12.7% | — | |
| LTM Mar 2026 | $22.46M | +252.3% | — | 19.2% | |
| LTM Mar 2026 | $6.68M | +141.4% | — | — | |
| LTM Mar 2026 | $5.27M | -92.9% | — | 70.3% | |
AGMBAgomAb Therapeutics N.V. American Depositary Shares | — | — | — | — | — |
| Peer median (excluding GYRE) | $5.27M | +141.4% | +12.7% | 70.3% | |
Competitors are the stored peer set for GYRE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (87.93M) | 4.31M | (85.48M) | 17.9M | 9.88M |
| Depreciation & Amortization | 290K | 1.13M | 1.11M | 1.59M | 2.48M |
| Deferred Income Tax | (3.89M) | (838K) | (1.16M) | (1M) | (1.11M) |
| Stock-Based Compensation | 3.41M | 13.37M | 7.28M | 831K | 7.16M |
| Change in Working Capital | 483K | (7.8M) | 7.46M | (15.69M) | (15.55M) |
| Accounts Receivables | 1.5M | (7.92M) | 1.3M | (9.29M) | (11.95M) |
| Inventory | 3.88M | (879K) | 1.75M | (2.14M) | (3.63M) |
| Accounts Payables | 500K | (112K) | 192K | (245K) | 13K |
| Other Working Capital | (5.39M) | 1.11M | 4.22M | (4.02M) | 17K |
| Other Non-Cash Items | 3.89M | 503K | 96.68M | (7.27M) | (1.85M) |
| Operating Cash Flow | (83.76M) | 10.68M | 25.89M | (3.64M) | 1.01M |
| Capital Expenditures | (839K) | (5M) | (8.59M) | (3.13M) | (1.19M) |
| Acquisitions (Net) | 0 | (1.33M) | 4.02M | (1.69M) | 30K |
| Purchases of Investments | 0 | (7.48M) | (15.74M) | (15.47M) | 0 |
| Sales of Investments | 49.03M | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | (13K) | 471K | (412K) | 686K |
| Investing Cash Flow | 48.19M | (13.81M) | (19.76M) | (19.88M) | (474K) |
| Debt Repayment | (6.7M) | 0 | 0 | 0 | 0 |
| Common Stock Issued | 49.55M | 0 | 0 | 773K | 25.87M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 6.7M | 0 | 0 | 1.33M | (1.49M) |
| Financing Cash Flow | 49.55M | 0 | 2.5M | 2.1M | 24.38M |
| Effect of Forex Changes | 0 | (1.89M) | (298K) | (273K) | 343K |
| Net Change in Cash | 13.99M | (5.03M) | 8.33M | (21.7M) | 25.26M |
| Free Cash Flow | (84.59M) | 5.68M | 17.31M | (6.77M) | (180K) |
Gyre Therapeutics, Inc.
NASDAQ:GYRE
Intrinsic Alpha fair value
Locked
Current Price
$4.34
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.